The present invention discloses the use of a mutant Leishmania as a suicidal vaccine wherein the mutant Leishmania is responsive to external signals to become porphyric and commit suicidal cytolysis. The mutant can be selected from natural Leishmania species or constructed by genetic engineering.

 
Web www.patentalert.com

> Genes encoding for genetic stability, gene expression and folding proteins

~ 00364